IOBT IO Biotech, Inc. revenue, earnings and financials
For the quarter ended September 30, 2025, IO Biotech, Inc. reported revenue of n/a, net income of −$8.38M and diluted EPS of −$0.13; for the fiscal year ended December 2024 revenue was n/a.
IOBT annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$95.2M, net income −$95.5M (margin n/a), EPS −$1.45
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$91.4M, net income −$86.1M (margin n/a), EPS −$1.98
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$71.4M, net income −$71.5M (margin n/a), EPS −$2.48
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$41.2M, net income −$67.9M (margin n/a), EPS −$17.30
IOBT quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.38M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$26.2M, EPS −$0.40
- Quarter ended Mar 31, 2025: revenue n/a, net income −$22.4M, EPS −$0.34
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$31.3M, EPS −$0.48
- Quarter ended Sep 30, 2024: revenue n/a, net income −$24.0M, EPS −$0.36
- Quarter ended Jun 30, 2024: revenue n/a, net income −$20.7M, EPS −$0.31
- Quarter ended Mar 31, 2024: revenue n/a, net income −$19.5M, EPS −$0.30
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$26.2M, EPS −$0.22
- Quarter ended Sep 30, 2023: revenue n/a, net income −$21.7M, EPS −$0.43
- Quarter ended Jun 30, 2023: revenue n/a, net income −$21.2M, EPS −$0.74
- Quarter ended Mar 31, 2023: revenue n/a, net income −$17.0M, EPS −$0.59
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$20.1M, EPS −$0.70
- Quarter ended Sep 30, 2022: revenue n/a, net income −$15.7M, EPS −$0.54
- Quarter ended Jun 30, 2022: revenue n/a, net income −$18.5M, EPS −$0.64
- Quarter ended Mar 31, 2022: revenue n/a, net income −$17.2M, EPS −$0.60
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$21.3M, EPS $279.40
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.46M, EPS −$36.88
- Quarter ended Jun 30, 2021: revenue n/a, net income −$38.4M, EPS −$228.29
- Quarter ended Mar 31, 2021: revenue n/a, net income −$3.75M, EPS −$31.53
IOBT cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$82.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$71.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$59.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$40.6M, share buybacks n/a
IOBT balance sheet
- Sep 30, 2025: cash $30.7M, total assets $40.0M, total liabilities $39.0M, shareholders' equity $911K, long-term debt $16.7M
- Jun 30, 2025: cash $28.1M, total assets $42.3M, total liabilities $40.7M, shareholders' equity $1.59M, long-term debt $6.72M
- Mar 31, 2025: cash $37.1M, total assets $45.7M, total liabilities $19.3M, shareholders' equity $26.4M, long-term debt $0
- Dec 31, 2024: cash $60.0M, total assets $67.7M, total liabilities $20.7M, shareholders' equity $47.0M, long-term debt $0
- Sep 30, 2024: cash $80.2M, total assets $89.9M, total liabilities $17.4M, shareholders' equity $72.6M
- Jun 30, 2024: cash $101M, total assets $111M, total liabilities $15.2M, shareholders' equity $96.3M
- Mar 31, 2024: cash $118M, total assets $128M, total liabilities $12.7M, shareholders' equity $115M
- Dec 31, 2023: cash $143M, total assets $151M, total liabilities $17.6M, shareholders' equity $133M
Is IOBT profitable?
No. IO Biotech, Inc. lost $88.4M over the last four quarters.
What is IOBT's EPS?
Diluted earnings per share over the last four quarters were −$1.35; −$0.13 in the latest quarter.